# US 10,118,929 B2 · Nonanoic and decanoic acid derivatives and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,118,929 B2
- Document ID: US10118929B2
- Status: Granted
- Kind: B2
- Application number: 15/498,736
- Filed: 2017-04-27
- Published: 2017-11-02
- Granted: 2018-11-06
- Earliest claimed: 2016-04-27
- Assignees: SciFluor Life Sciences, Inc.
- Applicants: SciFluor Life Sciences, Inc.
- Inventors: Takeru Furuya; Ben C. Askew
- Web page: https://patentgrep.com/patent/US10118929B2

## CPC

- C07D 487/04: Ortho-condensed systems
- C07D 233/36: with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present disclosure relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present disclosure also relates to pharmaceutical compositions containing the fluorinated compounds of the disclosure, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

## Claims

### Claim 1

A compound selected from the group consisting of:
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim 3 (depends on 1)

A method of treating a disease or condition mediated by an αv integrin in a subject, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof.

### Claim 4 (depends on 1)

The compound of claim 1, being
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 5 (depends on 1)

The compound of claim 1, being
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 6 (depends on 1)

The compound of claim 1, being
or a pharmaceutically acceptable salt or solvate thereof.